How much funding has Prosensa raised?

Prosensa has raised $30.0M in total funding, most recently a Series C round.

Who are Prosensa's investors?

Prosensa's investors include J.P. Morgan, Citi Ventures, SVB Leerink, New Enterprise Associates, BioMarin Pharmaceutical, Abingworth Bioventures.

Where is Prosensa headquartered?

Prosensa is headquartered in Leiden, Netherlands.

What industry is Prosensa in?

Prosensa operates in Biotech, RNA Therapeutics.

Prosensa

Closed

Leiden, Netherlands · Founded 2002 · $30.0M raised

Biotech

RNA Therapeutics

Headquarters: Leiden
Employees: 51–200
Founded: 2002
Business Model: B2B

Website: prosensa.eu
Total Funding: $30.0M
Last Round: $30.0M Series CJan 2012
Rounds: 1

About

Prosensa was a Leiden, Netherlands-based biopharmaceutical company focused on the discovery, development, and commercialization of RNA-modulating therapeutics for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. Founded in 2002, the company went public before being acquired by BioMarin Pharmaceutical in 2014 for approximately $680 million.

Summary

Prosensa is a Biotech company based in Leiden, Netherlands, founded in 2002. It has raised $30.0M in total across 1 round, most recently a $30.0M Series C round in Jan 2012. Investors include J.P. Morgan, Citi Ventures and SVB Leerink.